Coagulation Factor VIIa (Recombinant)

BIOLOGICAL3 trials

Sponsors

rEVO Biologics, Laboratoire français de Fractionnement et de Biotechnologies

Conditions

HemophiliaHemophilia A With InhibitorsHemophilia B With Inhibitors

Phase 3

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

CompletedNCT02020369

rEVO BiologicsHemophilia A With Inhibitors, Hemophilia B With Inhibitors

Start: 2014-04-30End: 2015-08-31Updated: 2017-06-14

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

CompletedNCT02548143

Laboratoire français de Fractionnement et de BiotechnologiesHemophilia

Start: 2016-08-25End: 2017-08-31Updated: 2022-02-25

Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery

TerminatedNCT05695391

Laboratoire français de Fractionnement et de BiotechnologiesHemophilia

Start: 2024-06-07End: 2025-07-07Updated: 2026-07-31

Related Papers

Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors.

PubMed2025-09-01

Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials.

2025-03-27

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Blood2024-11-05

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (&lt;12 years) with Hemophilia a or B with Inhibitors

Blood2023-11-021 citations

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Blood2022-11-151 citations

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Blood2022-11-15

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Blood2021-11-051 citations

PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Blood2020-11-04

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Blood2020-11-04